Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment Study for Patients with Non-Rhabdomyosarcoma Soft Tissue Sarcomas

Clinical Trial Title: 
Pazopanib neoadjuvant trial in non-rhabdomyosarcoma soft tissue sarcomas (PAZNTIS): A phase II/III randomized trial of preoperative chemoradiation or preoperative radiation plus or minus pazopanib.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To identify the dose of pazopanib that is feasible when given in combination with radiation or chemo-radiation in pediatric and adult patients with unresected intermediate- and high-risk NRSTS.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are older than 2 years of age at the time of the biopsy that established the diagnosis  of NRSTS.
  • Have been newly diagnosed and histopathologically confirmed, potentially resectable NRSTS of the extremity and trunk. Patients will be eligible for the chemotherapy or non-chemotherapy cohort based on:
    • Evidence of chemotherapy sensitivity of the histologic sarcoma subtype based on existing evidence from prior clinical trials.
    • Sufficient risk of metastatic disease to warrant chemotherapy based on size and grade.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane